| Code | Description | Claims | Beneficiaries | Total Paid |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
1,248,173 |
948,888 |
$115.81M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
158,886 |
130,232 |
$112.66M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
242,485 |
202,899 |
$95.16M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
231,095 |
202,783 |
$53.94M |
| J2350 |
Injection, ocrelizumab, 1 mg |
2,277 |
1,903 |
$41.48M |
| J9271 |
Injection, pembrolizumab, 1 mg |
6,184 |
4,226 |
$30.85M |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
138,750 |
111,516 |
$18.58M |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
84,180 |
47,252 |
$16.87M |
| J1459 |
Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg |
15,602 |
5,346 |
$16.81M |
| 42820 |
Tonsillectomy and adenoidectomy; younger than age 12 |
3,124 |
2,942 |
$15.57M |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
230,246 |
187,597 |
$15.16M |
| J1745 |
Injection, infliximab, excludes biosimilar, 10 mg |
7,958 |
5,726 |
$14.80M |
| 95004 |
Percutaneous tests with allergenic extracts, immediate type reaction |
4,951 |
4,349 |
$13.21M |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
178,678 |
69,004 |
$12.05M |
| J9299 |
Injection, nivolumab, 1 mg |
3,908 |
2,180 |
$11.48M |
| J2357 |
Injection, omalizumab, 5 mg |
8,650 |
4,467 |
$10.58M |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
31,253 |
28,349 |
$8.57M |
| J9312 |
Injection, rituximab, 10 mg |
2,754 |
1,495 |
$8.47M |
| J2323 |
Injection, natalizumab, 1 mg |
2,040 |
1,729 |
$8.13M |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
60,298 |
41,976 |
$7.70M |
| J9144 |
Injection, daratumumab, 10 mg and hyaluronidase-fihj |
2,727 |
1,551 |
$7.69M |
| J2505 |
Injection, pegfilgrastim, 6 mg |
3,437 |
2,233 |
$7.61M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
51,168 |
46,484 |
$7.17M |
| J0585 |
Injection, onabotulinumtoxina, 1 unit |
16,002 |
9,394 |
$7.06M |
| S9480 |
Intensive outpatient psychiatric services, per diem |
62,104 |
7,825 |
$6.88M |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
8,065 |
7,217 |
$6.69M |
| 71046 |
Radiologic examination, chest; 2 views |
131,644 |
114,469 |
$6.57M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
46,446 |
42,002 |
$6.30M |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
8,168 |
7,561 |
$6.07M |
| 95810 |
Polysomnography; sleep staging with 4 or more additional parameters |
7,603 |
7,016 |
$6.00M |
| 77386 |
|
23,963 |
1,597 |
$5.89M |
| J0490 |
Injection, belimumab, 10 mg |
4,354 |
1,974 |
$5.70M |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
41,549 |
33,454 |
$5.53M |
| 47562 |
|
1,303 |
1,218 |
$5.50M |
| 93303 |
Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study |
12,536 |
10,572 |
$5.26M |
| Q5107 |
Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg |
7,413 |
2,475 |
$5.10M |
| 59025 |
Fetal non-stress test |
32,174 |
16,196 |
$5.09M |
| 96361 |
Intravenous infusion, hydration; each additional hour |
98,749 |
74,288 |
$4.97M |
| 44970 |
|
986 |
916 |
$4.61M |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
22,273 |
20,235 |
$4.51M |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
10,671 |
9,816 |
$4.47M |
| J2353 |
Injection, octreotide, depot form for intramuscular injection, 1 mg |
1,472 |
1,186 |
$4.43M |
| 96375 |
Therapeutic injection; each additional sequential IV push |
114,091 |
79,489 |
$4.40M |
| J9035 |
Injection, bevacizumab, 10 mg |
2,503 |
942 |
$4.37M |
| J0741 |
Injection, cabotegravir and rilpivirine, 2mg/3mg |
1,016 |
888 |
$4.29M |
| 92587 |
|
17,211 |
15,365 |
$4.15M |
| J9022 |
Injection, atezolizumab, 10 mg |
1,335 |
849 |
$4.01M |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
191,595 |
155,260 |
$3.99M |
| J0897 |
Injection, denosumab, 1 mg |
5,714 |
4,678 |
$3.99M |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
19,116 |
17,291 |
$3.79M |
| 78815 |
Positron emission tomography (PET) for limited area imaging |
5,614 |
5,106 |
$3.78M |
| J3380 |
Injection, vedolizumab, intravenous, 1 mg |
857 |
768 |
$3.69M |
| Q5121 |
Injection, infliximab-axxq, biosimilar, (avsola), 10 mg |
2,690 |
2,146 |
$3.57M |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
34,076 |
30,651 |
$3.55M |
| Q5111 |
Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg |
1,393 |
903 |
$3.15M |
| J9355 |
Injection, trastuzumab, excludes biosimilar, 10 mg |
2,644 |
774 |
$2.96M |
| J9305 |
Injection, pemetrexed, not otherwise specified, 10 mg |
2,708 |
906 |
$2.94M |
| J1950 |
Injection, leuprolide acetate (for depot suspension), per 3.75 mg |
857 |
764 |
$2.89M |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
5,490 |
4,971 |
$2.78M |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
28,265 |
11,937 |
$2.72M |
| 58571 |
|
490 |
387 |
$2.69M |
| J0485 |
Injection, belatacept, 1 mg |
12,494 |
5,012 |
$2.69M |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
25,257 |
22,993 |
$2.61M |
| J9310 |
Injection, rituximab, 100 mg |
739 |
445 |
$2.59M |
| 38222 |
|
2,059 |
1,728 |
$2.52M |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
23,217 |
22,528 |
$2.47M |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
5,051 |
4,681 |
$2.46M |
| 58558 |
|
1,338 |
1,247 |
$2.42M |
| 93308 |
|
17,497 |
15,463 |
$2.39M |
| 70450 |
Computed tomography, head or brain; without contrast material |
50,048 |
43,995 |
$2.35M |
| 36430 |
|
11,282 |
5,653 |
$2.34M |
| 93976 |
|
24,638 |
21,645 |
$2.33M |
| 76825 |
|
5,056 |
4,333 |
$2.33M |
| J9306 |
Injection, pertuzumab, 1 mg |
857 |
542 |
$2.32M |
| 76811 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed |
11,376 |
10,504 |
$2.31M |
| 72125 |
Computed tomography, cervical spine; without contrast material |
26,609 |
23,605 |
$2.27M |
| 36561 |
|
1,301 |
1,186 |
$2.22M |
| Q0138 |
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) |
8,794 |
5,532 |
$2.17M |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
48,184 |
24,919 |
$2.14M |
| J9041 |
Injection, bortezomib, 0.1 mg |
11,602 |
1,889 |
$2.07M |
| J9311 |
Injection, rituximab 10 mg and hyaluronidase |
763 |
515 |
$2.06M |
| 45378 |
Colonoscopy, flexible; diagnostic, including collection of specimen(s) |
3,620 |
3,393 |
$2.05M |
| J9173 |
Injection, durvalumab, 10 mg |
612 |
309 |
$2.04M |
| Q5108 |
Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg |
1,656 |
1,004 |
$2.04M |
| 76830 |
Ultrasound, transvaginal |
20,735 |
19,102 |
$2.00M |
| 41899 |
Unlisted procedure, dentoalveolar structures |
5,161 |
4,616 |
$1.95M |
| G0379 |
Direct admission of patient for hospital observation care |
774 |
702 |
$1.93M |
| 42830 |
|
707 |
669 |
$1.92M |
| 86900 |
|
79,489 |
55,125 |
$1.91M |
| 95782 |
|
2,044 |
1,925 |
$1.90M |
| 66984 |
Extracapsular cataract removal with insertion of intraocular lens prosthesis |
2,381 |
1,940 |
$1.89M |
| 72197 |
|
5,516 |
5,082 |
$1.88M |
| 96415 |
|
27,631 |
19,423 |
$1.84M |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
30,783 |
24,108 |
$1.76M |
| 77412 |
|
15,073 |
1,558 |
$1.76M |
| Q5117 |
Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg |
2,106 |
1,248 |
$1.76M |
| 93458 |
|
1,159 |
1,062 |
$1.66M |
| 97162 |
|
31,477 |
28,624 |
$1.63M |
| 72156 |
|
3,695 |
3,366 |
$1.60M |
| 58661 |
|
394 |
367 |
$1.59M |
| J3032 |
Injection, eptinezumab-jjmr, 1 mg |
478 |
457 |
$1.56M |
| G0330 |
Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room |
2,079 |
1,498 |
$1.55M |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
79,927 |
70,194 |
$1.55M |
| 69436 |
Tympanostomy (requiring insertion of ventilating tube), general anesthesia |
2,501 |
2,332 |
$1.55M |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
77,155 |
70,137 |
$1.54M |
| 76770 |
|
18,393 |
17,011 |
$1.51M |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
11,371 |
10,356 |
$1.49M |
| 64721 |
|
1,246 |
1,163 |
$1.47M |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
66,446 |
56,143 |
$1.47M |
| 27447 |
|
175 |
160 |
$1.45M |
| 70498 |
|
8,595 |
7,773 |
$1.42M |
| J2506 |
Injection, pegfilgrastim, excludes biosimilar, 0.5 mg |
2,391 |
1,574 |
$1.41M |
| 74183 |
|
8,601 |
7,941 |
$1.40M |
| 82947 |
|
536,628 |
393,234 |
$1.36M |
| 96416 |
|
6,975 |
3,908 |
$1.34M |
| C8929 |
Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography |
6,337 |
5,761 |
$1.34M |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
111,242 |
82,830 |
$1.34M |
| P9016 |
Red blood cells, leukocytes reduced, each unit |
4,916 |
3,715 |
$1.32M |
| J9264 |
Injection, paclitaxel protein-bound particles, 1 mg |
2,119 |
576 |
$1.32M |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
12,292 |
10,931 |
$1.31M |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
10,582 |
9,722 |
$1.29M |
| 64493 |
|
1,660 |
1,514 |
$1.27M |
| 94060 |
|
6,418 |
5,349 |
$1.25M |
| 72141 |
|
5,625 |
5,231 |
$1.25M |
| 76801 |
|
11,547 |
10,256 |
$1.23M |
| 90870 |
|
5,298 |
2,003 |
$1.23M |
| 78431 |
|
1,890 |
1,715 |
$1.22M |
| Q5123 |
Injection, rituximab-arrx, biosimilar, (riabni), 10 mg |
790 |
349 |
$1.20M |
| 88184 |
|
9,997 |
8,022 |
$1.19M |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
6,066 |
5,607 |
$1.16M |
| J2182 |
Injection, mepolizumab, 1 mg |
780 |
638 |
$1.14M |
| P9073 |
Platelets, pheresis, pathogen-reduced, each unit |
2,809 |
968 |
$1.14M |
| 71045 |
Radiologic examination, chest; single view |
28,653 |
24,863 |
$1.12M |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
8,480 |
7,946 |
$1.11M |
| J0185 |
Injection, aprepitant, 1 mg |
8,648 |
4,753 |
$1.09M |
| 52000 |
|
4,185 |
3,833 |
$1.09M |
| 64615 |
|
7,707 |
5,272 |
$1.07M |
| 70544 |
|
3,235 |
2,936 |
$1.07M |
| 43235 |
|
2,390 |
2,167 |
$1.04M |
| 93971 |
|
16,018 |
14,382 |
$1.04M |
| J9316 |
Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg |
167 |
116 |
$1.03M |
| 90791 |
Psychiatric diagnostic evaluation |
11,381 |
9,986 |
$1.02M |
| 77334 |
|
3,934 |
2,716 |
$1.02M |
| J9358 |
Injection, fam-trastuzumab deruxtecan-nxki, 1 mg |
540 |
190 |
$1.01M |
| 64483 |
|
1,478 |
1,419 |
$1.01M |
| 93970 |
|
8,448 |
7,561 |
$1.01M |
| 71250 |
|
16,439 |
15,382 |
$996K |
| Q5119 |
Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg |
1,340 |
493 |
$983K |
| G0260 |
Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography |
2,262 |
2,041 |
$964K |
| 86902 |
|
1,913 |
1,370 |
$961K |
| 95911 |
|
2,356 |
2,250 |
$948K |
| 96409 |
|
6,177 |
3,899 |
$943K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
20,882 |
12,941 |
$940K |
| J0881 |
Injection, darbepoetin alfa, 1 microgram (non-esrd use) |
9,151 |
5,039 |
$937K |
| 64642 |
|
2,020 |
1,850 |
$890K |
| 84443 |
Thyroid stimulating hormone (TSH) |
153,221 |
136,021 |
$876K |
| 20610 |
|
4,900 |
4,372 |
$869K |
| J9217 |
Leuprolide acetate (for depot suspension), 7.5 mg |
4,086 |
3,463 |
$867K |
| P9040 |
Red blood cells, leukocytes reduced, irradiated, each unit |
4,282 |
2,244 |
$866K |
| 95812 |
|
3,670 |
3,471 |
$861K |
| C9399 |
Unclassified drugs or biologicals |
381 |
241 |
$845K |
| 77295 |
|
1,333 |
1,076 |
$840K |
| 70491 |
|
4,731 |
4,373 |
$839K |
| 19083 |
|
849 |
754 |
$823K |
| 96417 |
|
18,679 |
10,191 |
$817K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
797,602 |
571,780 |
$815K |
| 70543 |
|
1,814 |
1,656 |
$809K |
| 20680 |
|
856 |
782 |
$777K |
| 96900 |
|
30,080 |
5,431 |
$772K |
| 77301 |
|
1,293 |
1,048 |
$767K |
| 77066 |
Tomosynthesis, mammo |
6,750 |
6,371 |
$761K |
| J9070 |
Cyclophosphamide, 100 mg |
6,773 |
1,909 |
$758K |
| 95811 |
|
1,061 |
1,003 |
$748K |
| 27130 |
|
90 |
81 |
$737K |
| 97161 |
|
11,954 |
11,075 |
$731K |
| G2083 |
Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of greater than 56 mg esketamine nasal self-administration, includes 2 hours post-administration observation |
1,144 |
431 |
$729K |
| J1726 |
Injection, hydroxyprogesterone caproate, (makena), 10 mg |
1,199 |
395 |
$728K |
| 97535 |
Self-care/home management training, each 15 minutes |
21,668 |
15,734 |
$723K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
71,371 |
29,650 |
$721K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
20,774 |
17,793 |
$720K |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
31,400 |
14,748 |
$719K |
| G0390 |
Trauma response team associated with hospital critical care service |
1,053 |
923 |
$719K |
| 31575 |
|
5,979 |
5,377 |
$713K |
| 78451 |
|
1,458 |
1,345 |
$711K |
| 72100 |
|
22,614 |
21,190 |
$711K |
| 77336 |
|
10,076 |
4,054 |
$704K |
| 93454 |
|
669 |
615 |
$701K |
| 76536 |
|
10,111 |
9,593 |
$676K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
6,687 |
6,328 |
$674K |
| J9395 |
Injection, fulvestrant, 25 mg |
2,892 |
2,220 |
$666K |
| 10060 |
|
4,359 |
3,858 |
$662K |
| 52356 |
|
271 |
228 |
$658K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
8,354 |
7,732 |
$656K |
| 76641 |
|
7,867 |
7,450 |
$643K |
| 36512 |
|
779 |
612 |
$634K |
| 73564 |
|
23,912 |
22,026 |
$629K |
| 73030 |
|
26,264 |
23,909 |
$629K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
5,908 |
5,485 |
$628K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
14,708 |
7,184 |
$620K |
| 75561 |
|
2,193 |
2,002 |
$614K |
| 73610 |
|
26,744 |
23,829 |
$599K |
| 73221 |
|
3,354 |
3,083 |
$587K |
| 73630 |
|
29,888 |
27,040 |
$586K |
| 76642 |
|
10,616 |
9,865 |
$583K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
43,073 |
39,308 |
$580K |
| 62323 |
|
1,226 |
1,173 |
$577K |
| 86780 |
|
55,090 |
50,300 |
$572K |
| 96411 |
|
10,521 |
6,051 |
$567K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
62,588 |
57,471 |
$560K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
39,400 |
36,442 |
$559K |
| 83718 |
|
86,548 |
82,656 |
$558K |
| 54161 |
|
370 |
341 |
$549K |
| 76857 |
|
7,253 |
6,651 |
$548K |
| 0002A |
|
14,746 |
14,250 |
$545K |
| 77300 |
|
3,098 |
2,446 |
$543K |
| 0001A |
|
15,592 |
15,008 |
$533K |
| 73560 |
|
19,505 |
17,400 |
$518K |
| 31653 |
|
310 |
282 |
$502K |
| 20553 |
|
2,621 |
2,451 |
$493K |
| 81513 |
|
6,855 |
6,324 |
$489K |
| 93798 |
|
7,486 |
1,076 |
$488K |
| 95910 |
|
2,286 |
2,164 |
$487K |
| C9467 |
Injection, rituximab and hyaluronidase, 10 mg |
192 |
119 |
$485K |
| J7307 |
Etonogestrel (contraceptive) implant system, including implant and supplies |
1,581 |
1,336 |
$479K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
9,589 |
7,757 |
$474K |
| 92611 |
|
3,168 |
2,970 |
$472K |
| 95909 |
|
2,174 |
2,053 |
$467K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
3,615 |
3,461 |
$465K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
139,747 |
130,793 |
$464K |
| 86480 |
|
23,916 |
21,668 |
$459K |
| 36415 |
Collection of venous blood by venipuncture |
671,911 |
516,360 |
$456K |
| 36593 |
|
2,629 |
1,980 |
$451K |
| 90832 |
Psychotherapy, 30 minutes with patient |
10,706 |
5,999 |
$450K |
| 92523 |
|
1,973 |
1,854 |
$447K |
| 50200 |
|
641 |
584 |
$444K |
| 58662 |
|
180 |
158 |
$439K |
| 96367 |
|
10,205 |
6,629 |
$433K |
| 82247 |
|
377,988 |
292,268 |
$432K |
| 97166 |
|
6,745 |
6,094 |
$431K |
| 72158 |
|
3,621 |
3,334 |
$422K |
| 97116 |
|
13,635 |
7,826 |
$416K |
| 76819 |
Fetal biophysical profile; without non-stress testing |
4,173 |
2,073 |
$414K |
| 49083 |
|
924 |
576 |
$412K |
| J0561 |
Injection, penicillin g benzathine, 100,000 units |
2,200 |
1,854 |
$410K |
| J0129 |
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) |
341 |
292 |
$403K |
| 77065 |
Tomosynthesis, mammo |
3,754 |
3,551 |
$394K |
| 73502 |
|
17,737 |
16,340 |
$390K |
| 43237 |
|
464 |
429 |
$387K |
| 74178 |
|
2,017 |
1,865 |
$381K |
| 74230 |
|
3,531 |
3,320 |
$378K |
| 93975 |
|
2,362 |
2,114 |
$371K |
| 78816 |
|
566 |
517 |
$368K |
| 31231 |
|
2,440 |
2,236 |
$368K |
| 70496 |
|
9,068 |
8,219 |
$367K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
3,781 |
3,615 |
$362K |
| J2997 |
Injection, alteplase recombinant, 1 mg |
3,337 |
2,276 |
$361K |
| 78306 |
|
1,848 |
1,679 |
$361K |
| 95951 |
|
1,342 |
532 |
$355K |
| 78492 |
|
676 |
601 |
$354K |
| 82040 |
|
365,131 |
284,632 |
$354K |
| 82607 |
|
59,032 |
53,865 |
$350K |
| 43249 |
|
325 |
295 |
$348K |
| 92579 |
|
9,590 |
8,757 |
$346K |
| 64450 |
|
2,259 |
2,037 |
$346K |
| 81455 |
|
648 |
504 |
$343K |
| 93351 |
|
1,178 |
1,076 |
$341K |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
2,851 |
2,751 |
$336K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
4,311 |
3,751 |
$336K |
| 93017 |
|
10,862 |
9,858 |
$335K |
| 73522 |
|
6,644 |
6,309 |
$329K |
| 76882 |
|
7,173 |
6,649 |
$326K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
22,893 |
22,208 |
$326K |
| 73110 |
|
16,350 |
14,195 |
$322K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
1,112 |
1,003 |
$318K |
| 43276 |
|
118 |
102 |
$318K |
| 52310 |
|
326 |
299 |
$318K |
| 90834 |
Psychotherapy, 45 minutes with patient |
6,076 |
3,696 |
$315K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
59,625 |
48,802 |
$314K |
| 82728 |
|
82,553 |
73,341 |
$314K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
1,782 |
1,443 |
$311K |
| 10061 |
|
1,120 |
1,029 |
$310K |
| 73130 |
|
18,532 |
16,482 |
$309K |
| 97035 |
|
4,021 |
2,082 |
$309K |
| 47000 |
|
306 |
274 |
$306K |
| J7298 |
Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg |
1,258 |
1,039 |
$305K |
| 97165 |
|
3,976 |
3,714 |
$303K |
| 92012 |
Ophthalmological services: medical examination and evaluation, intermediate, established patient |
2,568 |
2,442 |
$300K |
| 86870 |
|
1,808 |
1,547 |
$296K |
| 72170 |
|
8,706 |
8,070 |
$294K |
| 51784 |
|
3,092 |
2,784 |
$292K |
| 43259 |
|
391 |
351 |
$292K |
| 86003 |
|
9,837 |
8,759 |
$289K |
| 95700 |
|
2,188 |
1,837 |
$285K |
| 95708 |
|
905 |
510 |
$284K |
| 93880 |
|
2,965 |
2,724 |
$272K |
| 86803 |
|
44,161 |
40,138 |
$271K |
| 30520 |
|
208 |
187 |
$267K |
| Q5101 |
Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram |
2,908 |
942 |
$264K |
| 87481 |
|
6,785 |
6,238 |
$264K |
| 77080 |
|
2,977 |
2,778 |
$258K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
230,577 |
187,668 |
$257K |
| 73562 |
|
7,577 |
7,220 |
$255K |
| 96450 |
|
1,065 |
787 |
$254K |
| J9042 |
Injection, brentuximab vedotin, 1 mg |
47 |
13 |
$253K |
| 92582 |
|
4,619 |
4,199 |
$249K |
| 93225 |
|
6,087 |
5,662 |
$246K |
| 90853 |
Group psychotherapy (other than of a multiple-family group) |
24,855 |
5,982 |
$244K |
| 93451 |
|
139 |
127 |
$243K |
| 92557 |
|
4,239 |
3,870 |
$242K |
| 92588 |
|
993 |
880 |
$241K |
| 95076 |
|
533 |
495 |
$239K |
| J1750 |
Injection, iron dextran, 50 mg |
1,298 |
1,166 |
$238K |
| 70486 |
|
8,440 |
7,761 |
$237K |
| 74174 |
|
1,728 |
1,547 |
$236K |
| 90651 |
|
1,465 |
1,259 |
$233K |
| 73700 |
|
3,101 |
2,870 |
$229K |
| C9062 |
Injection, daratumumab 10 mg and hyaluronidase-fihj |
106 |
45 |
$229K |
| 83013 |
|
4,705 |
4,457 |
$229K |
| 96401 |
|
13,717 |
5,526 |
$229K |
| 25605 |
|
182 |
170 |
$228K |
| 73140 |
|
10,355 |
9,090 |
$224K |
| J2796 |
Injection, romiplostim, 10 micrograms |
495 |
68 |
$222K |
| 93923 |
|
3,256 |
2,969 |
$222K |
| J9145 |
Injection, daratumumab, 10 mg |
336 |
83 |
$219K |
| 92526 |
|
2,380 |
1,465 |
$217K |
| 95715 |
|
699 |
409 |
$217K |
| 82310 |
|
516,547 |
380,204 |
$215K |
| 94010 |
|
15,254 |
12,106 |
$209K |
| 87506 |
|
3,748 |
3,376 |
$208K |
| 83970 |
|
19,453 |
16,790 |
$208K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
5,320 |
4,856 |
$206K |
| 94621 |
|
1,545 |
1,212 |
$200K |
| 72157 |
|
2,826 |
2,589 |
$198K |
| 20552 |
|
1,073 |
1,001 |
$195K |
| 58300 |
|
1,090 |
980 |
$195K |
| 87632 |
|
8,578 |
7,608 |
$191K |
| 86832 |
|
2,292 |
2,025 |
$189K |
| 43762 |
|
1,049 |
909 |
$188K |
| 72040 |
|
9,259 |
8,524 |
$187K |
| 83550 |
|
73,618 |
66,171 |
$185K |
| 72070 |
|
5,352 |
5,015 |
$185K |
| 77338 |
|
1,298 |
1,048 |
$181K |
| J9228 |
Injection, ipilimumab, 1 mg |
26 |
12 |
$181K |
| 81382 |
|
597 |
489 |
$176K |
| 92586 |
|
1,339 |
1,276 |
$175K |
| 77290 |
|
996 |
813 |
$175K |
| 71271 |
|
1,785 |
1,702 |
$171K |
| 86833 |
|
2,294 |
2,026 |
$169K |
| C8930 |
Transthoracic echocardiography, with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with physician supervision |
358 |
326 |
$166K |
| 97163 |
|
2,868 |
2,693 |
$166K |
| 74018 |
|
8,798 |
7,553 |
$164K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
113,452 |
97,321 |
$164K |
| 72146 |
|
2,255 |
2,070 |
$162K |
| 94375 |
|
10,884 |
9,226 |
$155K |
| 77072 |
|
3,708 |
3,467 |
$155K |
| 87536 |
|
14,782 |
13,334 |
$155K |
| 76818 |
|
1,496 |
1,060 |
$154K |
| 73590 |
|
11,173 |
9,891 |
$151K |
| 92610 |
|
905 |
832 |
$149K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
60,988 |
56,217 |
$149K |
| 75574 |
|
1,649 |
1,530 |
$149K |
| 96402 |
|
10,027 |
7,515 |
$148K |
| 20611 |
|
805 |
674 |
$148K |
| 90686 |
|
15,940 |
14,728 |
$148K |
| 70546 |
|
408 |
354 |
$147K |
| V5090 |
Dispensing fee, unspecified hearing aid |
367 |
284 |
$146K |
| 74220 |
|
1,541 |
1,440 |
$146K |
| 87653 |
|
10,352 |
9,614 |
$145K |
| 83540 |
|
78,117 |
69,815 |
$144K |
| 51700 |
|
1,163 |
909 |
$141K |
| 73080 |
|
8,968 |
8,019 |
$140K |
| 51729 |
|
356 |
338 |
$139K |
| 0012A |
|
3,814 |
3,654 |
$138K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
20,630 |
12,718 |
$138K |
| 72050 |
|
3,328 |
3,118 |
$137K |
| 95806 |
|
1,357 |
1,230 |
$133K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
38,594 |
31,965 |
$133K |
| 72082 |
|
4,744 |
4,463 |
$133K |
| 90837 |
Psychotherapy, 53 minutes with patient |
1,993 |
1,242 |
$133K |
| 77280 |
|
1,814 |
1,290 |
$132K |
| 92552 |
|
3,835 |
3,489 |
$131K |
| 87340 |
|
42,775 |
38,480 |
$131K |
| 36590 |
|
197 |
185 |
$131K |
| 0011A |
|
4,041 |
3,803 |
$130K |
| C9463 |
Injection, aprepitant, 1 mg |
771 |
364 |
$129K |
| 76813 |
|
2,606 |
2,446 |
$128K |
| 95908 |
|
583 |
565 |
$128K |
| 64447 |
|
1,741 |
1,600 |
$126K |
| 97760 |
|
3,173 |
2,736 |
$126K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
1,642 |
1,502 |
$126K |
| 78264 |
|
501 |
469 |
$125K |
| 90677 |
|
941 |
768 |
$124K |
| 84439 |
|
44,472 |
39,184 |
$123K |
| 29848 |
|
85 |
83 |
$123K |
| 51728 |
|
290 |
264 |
$123K |
| 10005 |
|
302 |
261 |
$121K |
| 84403 |
|
11,306 |
10,218 |
$120K |
| 82746 |
|
22,894 |
20,849 |
$120K |
| 92004 |
Ophthalmological services: medical examination and evaluation, comprehensive, new patient |
1,026 |
1,004 |
$120K |
| 90732 |
|
2,096 |
1,831 |
$117K |
| 90670 |
|
1,277 |
1,108 |
$114K |
| 82465 |
|
87,633 |
83,597 |
$114K |
| 73552 |
|
6,956 |
6,349 |
$113K |
| 74170 |
|
1,233 |
1,129 |
$113K |
| 51705 |
|
1,130 |
940 |
$112K |
| 49591 |
|
40 |
37 |
$110K |
| J1453 |
Injection, fosaprepitant, 1 mg |
2,912 |
1,703 |
$109K |
| 84702 |
|
43,425 |
32,350 |
$109K |
| 95953 |
|
301 |
188 |
$106K |
| 76000 |
|
1,644 |
1,518 |
$105K |
| 76870 |
|
5,339 |
4,843 |
$103K |
| 72110 |
|
3,154 |
2,971 |
$103K |
| 93304 |
|
252 |
217 |
$101K |
| J2356 |
Injection, tezepelumab-ekko, 1 mg |
42 |
37 |
$101K |
| 73120 |
|
2,470 |
2,237 |
$100K |
| 72195 |
|
545 |
500 |
$99K |
| 81220 |
CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants |
576 |
509 |
$99K |
| 26055 |
|
175 |
128 |
$97K |
| Q3014 |
Telehealth originating site facility fee |
15,934 |
13,422 |
$97K |
| 70487 |
|
774 |
701 |
$95K |
| J1610 |
Injection, glucagon hydrochloride, per 1 mg |
1,214 |
1,085 |
$94K |
| 73720 |
|
417 |
379 |
$94K |
| 86706 |
|
24,275 |
21,646 |
$93K |
| 82784 |
|
38,114 |
31,444 |
$93K |
| 96112 |
|
493 |
407 |
$92K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
18,282 |
17,084 |
$92K |
| 73718 |
|
480 |
446 |
$92K |
| 36522 |
|
32 |
13 |
$91K |
| 86923 |
|
8,388 |
5,421 |
$89K |
| 83655 |
|
22,657 |
18,761 |
$89K |
| 86235 |
|
5,515 |
4,815 |
$87K |
| 87522 |
Neg quan hep c or qual rna |
6,571 |
5,765 |
$86K |
| 64415 |
|
2,002 |
1,848 |
$86K |
| P9047 |
Infusion, albumin (human), 25%, 50 ml |
989 |
516 |
$86K |
| 72131 |
|
1,788 |
1,667 |
$86K |
| 29075 |
|
378 |
337 |
$84K |
| 36591 |
|
6,590 |
4,531 |
$84K |
| 92652 |
|
789 |
614 |
$83K |
| 70480 |
|
1,011 |
963 |
$83K |
| 77073 |
|
2,155 |
2,046 |
$83K |
| J9303 |
Injection, panitumumab, 10 mg |
53 |
12 |
$82K |
| 82570 |
|
58,408 |
50,294 |
$82K |
| 73200 |
|
1,128 |
1,056 |
$82K |
| 90675 |
|
305 |
142 |
$81K |
| 74240 |
|
623 |
587 |
$80K |
| 93926 |
|
1,733 |
1,492 |
$80K |
| 64616 |
|
766 |
660 |
$80K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
193 |
190 |
$80K |
| 72190 |
|
1,014 |
935 |
$80K |
| 77470 |
|
407 |
308 |
$79K |
| 36589 |
|
275 |
259 |
$79K |
| 36592 |
|
7,608 |
5,050 |
$78K |
| 85610 |
|
112,356 |
82,439 |
$78K |
| 57522 |
|
39 |
38 |
$77K |
| G0498 |
Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion |
665 |
400 |
$77K |
| 87631 |
|
4,018 |
3,753 |
$77K |
| 77062 |
|
6,023 |
5,698 |
$76K |
| 31624 |
|
276 |
239 |
$76K |
| 55700 |
|
99 |
91 |
$75K |
| 62270 |
|
152 |
136 |
$74K |
| 73070 |
|
4,045 |
3,498 |
$73K |
| 82374 |
|
531,694 |
389,526 |
$72K |
| 73090 |
|
8,478 |
7,298 |
$72K |
| 83735 |
|
158,103 |
105,360 |
$72K |
| 73000 |
|
2,621 |
2,300 |
$72K |
| J9171 |
Injection, docetaxel, 1 mg |
2,811 |
1,327 |
$72K |
| 86360 |
|
14,637 |
13,172 |
$72K |
| 99215 |
Prolong outpt/office vis |
627 |
569 |
$71K |
| 82670 |
|
6,047 |
5,482 |
$71K |
| 11100 |
|
336 |
299 |
$69K |
| 85027 |
|
65,685 |
50,551 |
$69K |
| 86140 |
|
62,754 |
53,782 |
$69K |
| 83001 |
|
8,913 |
8,078 |
$69K |
| 87497 |
|
10,988 |
6,029 |
$68K |
| 94660 |
|
3,871 |
1,955 |
$68K |
| C8924 |
Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, follow-up or limited study |
717 |
639 |
$68K |
| 86038 |
|
16,439 |
14,765 |
$67K |
| 86147 |
|
5,121 |
4,450 |
$67K |
| 83880 |
|
35,281 |
29,240 |
$67K |
| 49505 |
|
25 |
25 |
$66K |
| 72081 |
|
3,582 |
3,330 |
$65K |
| 86704 |
|
18,268 |
16,141 |
$65K |
| 95912 |
|
158 |
156 |
$65K |
| C8908 |
Magnetic resonance imaging without contrast followed by with contrast, breast; bilateral |
299 |
271 |
$65K |
| 84146 |
|
7,302 |
6,602 |
$64K |
| 11102 |
|
547 |
493 |
$64K |
| 81479 |
Unlisted molecular pathology procedure |
248 |
229 |
$63K |
| G0103 |
Prostate cancer screening; prostate specific antigen test (psa) |
6,132 |
5,586 |
$63K |
| 76885 |
|
877 |
833 |
$62K |
| 86905 |
|
732 |
600 |
$62K |
| 86618 |
|
9,135 |
8,406 |
$62K |
| 59820 |
|
25 |
24 |
$62K |
| 20605 |
|
360 |
320 |
$62K |
| 93296 |
|
3,920 |
3,809 |
$61K |
| J0517 |
Injection, benralizumab, 1 mg |
27 |
26 |
$61K |
| 84425 |
|
6,019 |
5,508 |
$61K |
| 83002 |
|
8,125 |
7,325 |
$60K |
| 84270 |
|
6,219 |
5,525 |
$59K |
| 29515 |
|
477 |
425 |
$59K |
| 82105 |
|
12,445 |
11,061 |
$59K |
| 81378 |
|
252 |
216 |
$58K |
| 86922 |
|
2,337 |
1,540 |
$58K |
| 86160 |
|
10,017 |
8,785 |
$58K |
| C9600 |
Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch |
13 |
12 |
$57K |
| 74160 |
|
684 |
644 |
$57K |
| 82043 |
|
26,998 |
24,604 |
$56K |
| 86146 |
|
4,269 |
3,750 |
$56K |
| 73060 |
|
4,791 |
4,282 |
$56K |
| 30140 |
|
201 |
188 |
$55K |
| 80061 |
Lipid panel |
30,455 |
26,764 |
$55K |
| 64635 |
|
39 |
36 |
$55K |
| Q9950 |
Injection, sulfur hexafluoride lipid microspheres, per ml |
7,183 |
4,823 |
$55K |
| 58301 |
|
329 |
312 |
$54K |
| 37243 |
|
13 |
12 |
$54K |
| 87186 |
|
32,466 |
28,980 |
$54K |
| 90746 |
|
1,484 |
1,345 |
$53K |
| 81001 |
|
132,408 |
113,348 |
$53K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,692 |
1,483 |
$52K |
| 57454 |
|
220 |
204 |
$52K |
| 97542 |
|
2,203 |
1,771 |
$51K |
| M0222 |
Intravenous injection, bebtelovimab, includes injection and post administration monitoring |
231 |
203 |
$51K |
| 83721 |
|
12,038 |
11,208 |
$51K |
| 51725 |
|
283 |
267 |
$51K |
| G0399 |
Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation |
448 |
425 |
$50K |
| 80197 |
|
21,084 |
11,040 |
$50K |
| 92651 |
|
406 |
330 |
$48K |
| 99195 |
|
1,027 |
829 |
$47K |
| 85055 |
|
24,153 |
12,836 |
$47K |
| 87077 |
|
28,081 |
25,098 |
$47K |
| 86008 |
|
1,506 |
1,325 |
$47K |
| 87799 |
|
7,379 |
5,196 |
$47K |
| J0739 |
Injection, cabotegravir, 1mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv) |
12 |
12 |
$46K |
| 84153 |
|
11,390 |
9,775 |
$46K |
| J9202 |
Goserelin acetate implant, per 3.6 mg |
78 |
65 |
$46K |
| 84478 |
|
83,544 |
77,291 |
$46K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
31,960 |
28,474 |
$46K |
| 74181 |
|
575 |
522 |
$46K |
| 83516 |
|
8,804 |
7,588 |
$45K |
| 84480 |
|
7,501 |
6,539 |
$44K |
| 84402 |
|
3,971 |
3,620 |
$44K |
| 90378 |
|
18 |
16 |
$43K |
| 66982 |
|
47 |
42 |
$43K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
16,629 |
13,267 |
$43K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
57,921 |
34,481 |
$43K |
| 96910 |
|
2,437 |
597 |
$43K |
| 81508 |
|
1,442 |
1,362 |
$43K |
| 86708 |
|
9,946 |
8,757 |
$43K |
| 64400 |
|
190 |
173 |
$43K |
| 51702 |
|
2,350 |
2,020 |
$42K |
| J9075 |
Injection, cyclophosphamide, not otherwise specified, 5 mg |
697 |
186 |
$42K |
| 84445 |
|
2,221 |
2,030 |
$42K |
| G0378 |
Hospital observation service, per hour |
99,325 |
74,304 |
$41K |
| 64999 |
|
2,002 |
1,779 |
$41K |
| 86334 |
|
11,858 |
10,155 |
$41K |
| 90935 |
Hemodialysis procedure with single evaluation by a physician |
1,501 |
853 |
$41K |
| 93925 |
|
485 |
455 |
$41K |
| 92585 |
|
225 |
205 |
$40K |
| 96523 |
|
2,776 |
2,171 |
$39K |
| 95813 |
|
425 |
367 |
$39K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
14,986 |
14,020 |
$39K |
| 71101 |
|
3,472 |
3,201 |
$38K |
| J1930 |
Injection, lanreotide, 1 mg |
18 |
12 |
$38K |
| 97763 |
|
2,180 |
1,652 |
$38K |
| 74241 |
|
206 |
203 |
$38K |
| 81206 |
|
2,367 |
1,904 |
$38K |
| 95117 |
|
997 |
566 |
$37K |
| 82951 |
|
3,373 |
3,219 |
$37K |
| 86787 |
|
13,486 |
12,254 |
$36K |
| 29581 |
|
511 |
381 |
$35K |
| 82950 |
|
9,055 |
8,568 |
$35K |
| 86762 |
|
14,799 |
13,422 |
$35K |
| 80053 |
Comprehensive metabolic panel |
191,155 |
130,646 |
$35K |
| 85730 |
|
49,803 |
38,764 |
$35K |
| V5011 |
Fitting/orientation/checking of hearing aid |
1,258 |
990 |
$34K |
| 83921 |
|
7,632 |
6,880 |
$34K |
| 82785 |
|
8,427 |
7,292 |
$34K |
| 85652 |
|
50,395 |
44,447 |
$34K |
| 76080 |
|
138 |
105 |
$34K |
| 77373 |
|
53 |
12 |
$33K |
| 86769 |
|
1,028 |
929 |
$33K |
| J1729 |
Injection, hydroxyprogesterone caproate, not otherwise specified, 10 mg |
175 |
59 |
$33K |
| 77061 |
|
2,784 |
2,644 |
$33K |
| 54640 |
|
14 |
12 |
$33K |
| 51798 |
|
19,586 |
17,522 |
$32K |
| 74019 |
|
3,183 |
2,814 |
$32K |
| 64454 |
|
115 |
109 |
$32K |
| V5264 |
Ear mold/insert, not disposable, any type |
1,164 |
931 |
$32K |
| 86830 |
|
624 |
572 |
$32K |
| 87529 |
|
3,114 |
2,799 |
$32K |
| 92511 |
|
219 |
201 |
$32K |
| 83520 |
|
5,496 |
4,722 |
$31K |
| 83525 |
|
5,497 |
4,765 |
$31K |
| 82627 |
|
3,664 |
3,317 |
$31K |
| 97755 |
|
2,277 |
1,750 |
$31K |
| 88342 |
|
8,545 |
7,439 |
$31K |
| 86682 |
|
2,331 |
1,912 |
$30K |
| 87517 |
|
2,574 |
2,248 |
$30K |
| 83521 |
|
8,912 |
7,659 |
$30K |
| 81003 |
|
79,566 |
70,910 |
$29K |
| 95712 |
|
184 |
163 |
$29K |
| 73660 |
|
2,853 |
2,602 |
$29K |
| 86765 |
|
3,948 |
3,532 |
$29K |
| J2315 |
Injection, naltrexone, depot form, 1 mg |
46 |
37 |
$28K |
| 86735 |
|
3,494 |
3,159 |
$28K |
| 86665 |
|
5,182 |
3,881 |
$28K |
| 82652 |
|
1,485 |
1,337 |
$28K |
| 86225 |
|
7,763 |
6,825 |
$28K |
| 82533 |
|
5,900 |
4,669 |
$28K |
| 87070 |
|
20,645 |
17,286 |
$27K |
| 86696 |
|
2,986 |
2,641 |
$27K |
| 86831 |
|
624 |
572 |
$27K |
| 84165 |
|
18,095 |
15,405 |
$27K |
| 0031A |
|
1,839 |
873 |
$27K |
| 74455 |
|
192 |
174 |
$27K |
| 83014 |
|
4,672 |
4,429 |
$27K |
| Q0222 |
Injection, bebtelovimab, 175 mg |
17 |
16 |
$26K |
| 83690 |
|
100,453 |
84,467 |
$25K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
2,858 |
2,574 |
$25K |
| 95819 |
|
119 |
111 |
$25K |
| 43264 |
|
80 |
75 |
$25K |
| 83021 |
|
13,941 |
11,675 |
$25K |
| 76604 |
|
1,677 |
1,557 |
$25K |
| G0297 |
Low dose ct scan (ldct) for lung cancer screening |
376 |
359 |
$24K |
| 94726 |
|
1,316 |
913 |
$24K |
| 86376 |
|
5,661 |
5,138 |
$24K |
| 75716 |
|
41 |
39 |
$23K |
| 82088 |
|
1,431 |
1,208 |
$23K |
| 74221 |
|
172 |
164 |
$23K |
| 84156 |
|
34,120 |
28,521 |
$23K |
| 84207 |
|
1,909 |
1,736 |
$23K |
| J9155 |
Injection, degarelix, 1 mg |
217 |
195 |
$23K |
| 94728 |
|
2,553 |
2,365 |
$23K |
| 84630 |
|
3,915 |
3,611 |
$23K |
| 91122 |
|
132 |
113 |
$22K |
| 42821 |
|
18 |
14 |
$22K |
| A9595 |
Piflufolastat f-18, diagnostic, 1 millicurie |
26 |
24 |
$22K |
| 67311 |
|
12 |
12 |
$22K |
| 86359 |
|
14,643 |
13,179 |
$22K |
| 86800 |
|
4,447 |
4,037 |
$22K |
| 82248 |
|
154,825 |
127,534 |
$22K |
| 93786 |
|
295 |
265 |
$22K |
| 85245 |
|
4,150 |
3,593 |
$22K |
| 93990 |
|
900 |
813 |
$21K |
| 95816 |
|
89 |
82 |
$21K |
| 58100 |
|
145 |
140 |
$21K |
| 86705 |
|
5,232 |
4,822 |
$21K |
| 82024 |
|
1,516 |
1,342 |
$21K |
| 64445 |
|
536 |
491 |
$21K |
| 82378 |
|
14,809 |
11,874 |
$21K |
| 86850 |
|
76,535 |
53,220 |
$21K |
| 88304 |
|
7,557 |
6,941 |
$21K |
| P9037 |
Platelets, pheresis, leukocytes reduced, irradiated, each unit |
51 |
27 |
$20K |
| 83883 |
|
8,133 |
6,595 |
$20K |
| 97129 |
|
255 |
89 |
$20K |
| 83498 |
|
2,180 |
1,949 |
$20K |
| 92950 |
|
130 |
118 |
$20K |
| 70360 |
|
1,696 |
1,590 |
$20K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
3,460 |
3,164 |
$20K |
| 86364 |
|
5,142 |
4,715 |
$20K |
| 76775 |
|
2,633 |
2,425 |
$20K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
96,773 |
64,472 |
$20K |
| J1611 |
Injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to j1610, per 1 mg |
425 |
380 |
$19K |
| 54163 |
|
14 |
12 |
$19K |
| 73521 |
|
1,018 |
958 |
$19K |
| M0239 |
Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring |
98 |
66 |
$19K |
| 11721 |
|
1,937 |
1,775 |
$19K |
| 90662 |
|
3,158 |
2,808 |
$19K |
| 85244 |
|
4,159 |
3,616 |
$19K |
| 86695 |
|
2,986 |
2,641 |
$19K |
| 80177 |
|
5,668 |
4,940 |
$19K |
| 85240 |
|
4,813 |
4,085 |
$18K |
| 83993 |
|
1,614 |
1,513 |
$18K |
| 64612 |
|
120 |
116 |
$18K |
| G0279 |
Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) |
556 |
529 |
$18K |
| 41010 |
|
15 |
13 |
$18K |
| 11981 |
|
357 |
320 |
$18K |
| 43760 |
|
70 |
65 |
$18K |
| 52287 |
|
27 |
24 |
$18K |
| 86709 |
|
4,603 |
4,226 |
$17K |
| 87088 |
|
10,712 |
9,742 |
$17K |
| 52332 |
|
12 |
12 |
$17K |
| 98967 |
|
971 |
297 |
$17K |
| 86431 |
|
8,551 |
7,793 |
$17K |
| 73100 |
|
1,682 |
1,435 |
$17K |
| 86200 |
|
4,551 |
4,115 |
$17K |
| 94664 |
|
6,058 |
5,378 |
$17K |
| 87338 |
|
1,863 |
1,794 |
$17K |
| 86255 |
|
2,445 |
1,896 |
$16K |
| 38505 |
|
34 |
27 |
$16K |
| 91120 |
|
88 |
83 |
$16K |
| 31628 |
|
51 |
51 |
$16K |
| 93242 |
|
1,145 |
1,055 |
$16K |
| 84305 |
|
3,231 |
2,957 |
$16K |
| 83519 |
|
2,558 |
2,199 |
$16K |
| 95713 |
|
56 |
49 |
$16K |
| 86039 |
|
4,720 |
4,216 |
$16K |
| 45381 |
|
42 |
37 |
$16K |
| 84432 |
|
2,755 |
2,250 |
$16K |
| 62321 |
|
25 |
25 |
$15K |
| 73650 |
|
704 |
643 |
$15K |
| 80164 |
|
5,218 |
4,378 |
$15K |
| 88142 |
|
1,428 |
1,338 |
$15K |
| 31526 |
|
14 |
13 |
$15K |
| 78582 |
|
97 |
76 |
$15K |
| C9447 |
Injection, phenylephrine and ketorolac, 4 ml vial |
139 |
110 |
$15K |
| 0240U |
|
122 |
118 |
$15K |
| 82397 |
|
3,498 |
3,174 |
$15K |
| 91010 |
|
45 |
41 |
$15K |
| 85598 |
|
3,695 |
3,261 |
$14K |
| 72220 |
|
920 |
865 |
$14K |
| 51720 |
|
94 |
49 |
$14K |
| 90792 |
Psychiatric diagnostic evaluation with medical services |
113 |
109 |
$14K |
| 83090 |
|
3,390 |
3,013 |
$14K |
| 85046 |
|
24,846 |
18,233 |
$14K |
| 87205 |
|
19,822 |
16,290 |
$14K |
| 71100 |
|
896 |
852 |
$14K |
| G0257 |
Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility |
1,007 |
510 |
$14K |
| G0424 |
Pulmonary rehabilitation, including exercise (includes monitoring), one hour, per session, up to two sessions per day |
660 |
141 |
$14K |
| 84244 |
|
1,595 |
1,466 |
$14K |
| 70481 |
|
104 |
99 |
$14K |
| 95250 |
|
154 |
135 |
$13K |
| 87640 |
|
1,701 |
1,541 |
$13K |
| 81025 |
|
105,382 |
91,384 |
$13K |
| 92960 |
|
54 |
54 |
$13K |
| G2066 |
Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results |
1,961 |
1,851 |
$13K |
| 85007 |
|
34,823 |
25,554 |
$13K |
| 86304 |
|
5,811 |
4,476 |
$13K |
| 86258 |
|
2,165 |
1,973 |
$13K |
| 80175 |
|
2,727 |
2,379 |
$13K |
| P9041 |
Infusion, albumin (human), 5%, 50 ml |
40 |
24 |
$13K |
| 84460 |
|
385,201 |
301,303 |
$13K |
| 87081 |
|
6,899 |
6,317 |
$13K |
| 72080 |
|
584 |
561 |
$12K |
| 86664 |
|
4,805 |
3,883 |
$12K |
| 97032 |
|
146 |
79 |
$12K |
| 73600 |
|
739 |
588 |
$12K |
| 82157 |
|
1,402 |
1,237 |
$12K |
| 87209 |
|
1,884 |
1,652 |
$12K |
| M0247 |
Intravenous infusion, sotrovimab, includes infusion and post administration monitoring |
39 |
36 |
$12K |
| M0245 |
Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring |
63 |
37 |
$12K |
| 85379 |
|
22,271 |
19,440 |
$12K |
| 29065 |
|
51 |
45 |
$12K |
| 0071A |
|
336 |
301 |
$12K |
| G0239 |
Therapeutic procedures to improve respiratory function or increase strength or endurance of respiratory muscles, two or more individuals (includes monitoring) |
807 |
169 |
$12K |
| 10022 |
|
30 |
25 |
$11K |
| 10120 |
|
42 |
38 |
$11K |
| 88307 |
|
4,844 |
4,158 |
$11K |
| 94618 |
|
3,237 |
2,296 |
$11K |
| 92567 |
|
25,071 |
22,569 |
$11K |
| 0072A |
|
296 |
296 |
$11K |
| 88300 |
|
7,205 |
6,539 |
$11K |
| 46607 |
|
27 |
25 |
$11K |
| 17250 |
|
1,230 |
1,098 |
$11K |
| 86592 |
|
3,324 |
3,060 |
$11K |
| 86341 |
|
945 |
845 |
$11K |
| 86301 |
|
5,286 |
4,241 |
$11K |
| 95913 |
|
27 |
24 |
$10K |
| 19081 |
|
18 |
15 |
$10K |
| 72128 |
|
200 |
178 |
$10K |
| 11056 |
|
314 |
285 |
$10K |
| 64490 |
|
13 |
13 |
$10K |
| 72072 |
|
773 |
712 |
$10K |
| 93299 |
|
491 |
476 |
$10K |
| 83010 |
|
9,418 |
5,574 |
$10K |
| 82565 |
|
552,767 |
399,288 |
$10K |
| 28285 |
|
14 |
12 |
$10K |
| 72120 |
|
392 |
376 |
$9K |
| 87449 |
|
4,230 |
3,597 |
$9K |
| 86335 |
|
3,226 |
2,756 |
$9K |
| 97014 |
|
149 |
70 |
$9K |
| 87324 |
|
2,923 |
2,600 |
$9K |
| 97597 |
|
123 |
105 |
$9K |
| 73620 |
|
429 |
298 |
$9K |
| 82139 |
|
1,619 |
1,292 |
$9K |
| P9011 |
Blood, split unit |
143 |
67 |
$9K |
| 92551 |
|
1,452 |
1,388 |
$9K |
| 87177 |
|
1,861 |
1,668 |
$9K |
| 86300 |
|
6,726 |
5,167 |
$9K |
| 91040 |
|
38 |
30 |
$9K |
| 84166 |
|
3,386 |
2,903 |
$8K |
| 76826 |
|
35 |
28 |
$8K |
| 82390 |
|
2,777 |
2,506 |
$8K |
| 14060 |
|
15 |
13 |
$8K |
| 98968 |
|
506 |
137 |
$8K |
| 84134 |
|
1,888 |
1,677 |
$8K |
| 82150 |
|
4,839 |
3,553 |
$8K |
| 85613 |
|
3,759 |
3,271 |
$8K |
| 43238 |
|
13 |
12 |
$8K |
| 80183 |
|
2,006 |
1,757 |
$8K |
| 82787 |
|
1,680 |
1,415 |
$8K |
| 87075 |
|
9,520 |
7,604 |
$8K |
| 86812 |
|
1,123 |
1,044 |
$8K |
| 49452 |
|
12 |
12 |
$8K |
| 24640 |
|
43 |
36 |
$8K |
| 91322 |
|
320 |
269 |
$8K |
| 82952 |
|
2,835 |
2,607 |
$8K |
| 82164 |
|
1,813 |
1,575 |
$8K |
| 17110 |
|
407 |
358 |
$8K |
| 80299 |
|
1,605 |
1,352 |
$7K |
| 74175 |
|
646 |
559 |
$7K |
| 86617 |
|
718 |
612 |
$7K |
| J2597 |
Injection, desmopressin acetate, per 1 mcg |
258 |
233 |
$7K |
| 57455 |
|
32 |
29 |
$7K |
| 31267 |
|
14 |
13 |
$7K |
| 82140 |
|
4,503 |
3,760 |
$7K |
| 86880 |
|
2,898 |
2,445 |
$7K |
| 82550 |
|
22,480 |
18,808 |
$7K |
| 82103 |
|
1,802 |
1,485 |
$7K |
| 86021 |
|
2,113 |
1,676 |
$7K |
| 0054A |
|
348 |
254 |
$7K |
| 75580 |
|
17 |
12 |
$7K |
| 73723 |
|
31 |
27 |
$7K |
| 82542 |
|
1,023 |
884 |
$7K |
| 84484 |
|
135,407 |
69,868 |
$7K |
| 12001 |
|
5,281 |
4,891 |
$7K |
| 84481 |
|
1,450 |
1,115 |
$7K |
| 45331 |
|
14 |
12 |
$6K |
| 84144 |
|
499 |
438 |
$6K |
| 80156 |
|
1,441 |
1,216 |
$6K |
| 11982 |
|
30 |
29 |
$6K |
| 83615 |
|
56,163 |
38,635 |
$6K |
| J1097 |
Phenylephrine 10.16 mg/ml and ketorolac 2.88 mg/ml ophthalmic irrigation solution, 1 ml |
53 |
46 |
$6K |
| 82525 |
|
1,839 |
1,623 |
$6K |
| 91035 |
|
12 |
12 |
$6K |
| 12011 |
|
4,380 |
4,041 |
$6K |
| 82085 |
|
1,915 |
1,683 |
$6K |
| 90480 |
|
349 |
293 |
$6K |
| 86381 |
|
684 |
599 |
$6K |
| 70250 |
|
471 |
406 |
$6K |
| Q9968 |
Injection, non-radioactive, non-contrast, visualization adjunct (e.g., methylene blue, isosulfan blue), 1 mg |
590 |
280 |
$6K |
| 72192 |
|
113 |
104 |
$6K |
| 31500 |
|
52 |
49 |
$5K |
| 92522 |
|
28 |
26 |
$5K |
| 86316 |
|
1,724 |
1,453 |
$5K |
| M0220 |
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring |
64 |
54 |
$5K |
| 59841 |
|
144 |
101 |
$5K |
| 92612 |
|
64 |
53 |
$5K |
| 11900 |
|
309 |
274 |
$5K |
| 81596 |
|
141 |
127 |
$5K |
| 81269 |
|
46 |
43 |
$5K |
| 87300 |
|
923 |
867 |
$5K |
| 97167 |
|
95 |
89 |
$5K |
| J7342 |
Instillation, ciprofloxacin otic suspension, 6 mg |
247 |
202 |
$5K |
| 82239 |
|
639 |
483 |
$5K |
| 97022 |
|
64 |
42 |
$5K |
| 0124A |
|
244 |
223 |
$5K |
| 85306 |
|
1,447 |
1,227 |
$5K |
| J2310 |
Injection, naloxone hydrochloride, per 1 mg |
1,766 |
1,372 |
$5K |
| 87808 |
|
4,316 |
4,023 |
$5K |
| 69210 |
|
2,777 |
2,576 |
$5K |
| 83835 |
|
827 |
739 |
$5K |
| 82232 |
|
2,464 |
2,070 |
$5K |
| 72193 |
|
46 |
41 |
$5K |
| 84202 |
|
515 |
502 |
$5K |
| 86357 |
|
2,711 |
2,354 |
$5K |
| 86355 |
|
2,703 |
2,347 |
$5K |
| 91200 |
|
43 |
40 |
$5K |
| 51741 |
|
2,776 |
2,567 |
$5K |
| 86256 |
|
299 |
257 |
$5K |
| 0004A |
|
221 |
126 |
$5K |
| 87015 |
|
6,066 |
4,642 |
$4K |
| 81372 |
|
32 |
24 |
$4K |
| 84450 |
|
370,944 |
289,664 |
$4K |
| 19301 |
|
17 |
12 |
$4K |
| 31615 |
|
15 |
14 |
$4K |
| 84154 |
|
733 |
667 |
$4K |
| 74740 |
|
17 |
17 |
$4K |
| 97164 |
|
427 |
399 |
$4K |
| 86015 |
|
1,301 |
1,163 |
$4K |
| 90833 |
Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) |
170 |
125 |
$4K |
| 82274 |
|
391 |
376 |
$4K |
| 83020 |
|
591 |
539 |
$4K |
| 86645 |
|
2,688 |
2,008 |
$4K |
| 87493 |
|
603 |
558 |
$4K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
282 |
261 |
$4K |
| 86644 |
|
3,806 |
2,933 |
$4K |
| 82435 |
|
509,162 |
374,769 |
$4K |
| 94625 |
|
448 |
85 |
$4K |
| 86580 |
|
1,107 |
1,042 |
$4K |
| 80178 |
|
2,876 |
2,261 |
$4K |
| 82340 |
|
2,026 |
1,850 |
$4K |
| 87116 |
|
2,727 |
2,071 |
$4K |
| 87102 |
|
3,831 |
3,041 |
$4K |
| 86593 |
|
1,077 |
977 |
$4K |
| 82166 |
|
285 |
264 |
$4K |
| 76820 |
|
6,047 |
2,049 |
$4K |
| 84410 |
|
111 |
88 |
$4K |
| 84145 |
|
11,599 |
9,552 |
$4K |
| 93271 |
|
54 |
51 |
$4K |
| 80235 |
|
635 |
548 |
$4K |
| P9604 |
Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge |
3,081 |
1,787 |
$4K |
| 82379 |
|
782 |
679 |
$3K |
| 84681 |
|
501 |
455 |
$3K |
| 89051 |
|
6,034 |
4,162 |
$3K |
| 85018 |
|
25,638 |
19,326 |
$3K |
| J0612 |
Injection, calcium gluconate, not otherwise specified, 10 mg |
964 |
642 |
$3K |
| 88360 |
|
2,898 |
2,430 |
$3K |
| 82803 |
|
53,276 |
42,204 |
$3K |
| 85303 |
|
1,153 |
1,024 |
$3K |
| 76821 |
|
855 |
385 |
$3K |
| 20550 |
|
12 |
12 |
$3K |
| 82668 |
|
1,619 |
1,364 |
$3K |
| 86036 |
|
1,088 |
910 |
$3K |
| 91065 |
|
27 |
25 |
$3K |
| 83605 |
|
57,427 |
44,554 |
$3K |
| 81207 |
|
380 |
306 |
$3K |
| 84436 |
|
1,285 |
1,191 |
$3K |
| 87252 |
|
425 |
402 |
$3K |
| 94680 |
|
668 |
592 |
$3K |
| 85300 |
|
1,402 |
1,165 |
$3K |
| 84446 |
|
727 |
642 |
$3K |
| 87329 |
|
510 |
462 |
$3K |
| 87902 |
|
44 |
40 |
$3K |
| 94642 |
|
1,825 |
1,573 |
$3K |
| 87040 |
|
16,377 |
8,694 |
$3K |
| 85576 |
|
743 |
686 |
$3K |
| 86666 |
|
435 |
292 |
$3K |
| 92555 |
|
2,638 |
2,393 |
$3K |
| 85384 |
|
5,718 |
4,266 |
$3K |
| 87101 |
|
674 |
608 |
$3K |
| 87184 |
|
2,463 |
2,171 |
$3K |
| 96377 |
|
4,723 |
3,140 |
$3K |
| 88112 |
|
3,721 |
3,194 |
$3K |
| 80076 |
|
4,295 |
3,601 |
$3K |
| 73503 |
|
84 |
78 |
$3K |
| 87206 |
|
3,643 |
2,926 |
$3K |
| 92570 |
|
66 |
56 |
$3K |
| 93979 |
|
127 |
119 |
$3K |
| 83695 |
|
459 |
424 |
$3K |
| 86317 |
|
1,294 |
800 |
$3K |
| 93888 |
|
34 |
24 |
$3K |
| 80184 |
|
7,926 |
7,114 |
$3K |
| 85014 |
|
42,911 |
36,820 |
$3K |
| 12002 |
|
2,783 |
2,560 |
$3K |
| 92609 |
|
31 |
12 |
$2K |
| 91037 |
|
12 |
12 |
$2K |
| 77332 |
|
42 |
36 |
$2K |
| 84590 |
|
719 |
640 |
$2K |
| 84550 |
|
24,394 |
18,361 |
$2K |
| 85520 |
|
827 |
552 |
$2K |
| 81050 |
|
1,676 |
1,552 |
$2K |
| 80185 |
|
655 |
544 |
$2K |
| 87625 |
|
190 |
180 |
$2K |
| 57452 |
|
16 |
14 |
$2K |
| 86308 |
|
2,041 |
1,870 |
$2K |
| 82330 |
|
42,110 |
36,325 |
$2K |
| 82172 |
|
354 |
325 |
$2K |
| 93280 |
|
2,563 |
2,296 |
$2K |
| 87484 |
|
320 |
293 |
$2K |
| 87468 |
|
320 |
293 |
$2K |
| 93312 |
|
16 |
13 |
$2K |
| 86753 |
|
320 |
300 |
$2K |
| 84100 |
|
66,964 |
46,052 |
$2K |
| 76828 |
|
156 |
118 |
$2K |
| 81270 |
|
780 |
650 |
$2K |
| L1830 |
Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf |
34 |
29 |
$2K |
| 84600 |
|
3,317 |
2,895 |
$2K |
| 81002 |
|
74,957 |
61,477 |
$2K |
| 80201 |
|
484 |
440 |
$2K |
| 84300 |
|
2,775 |
2,367 |
$2K |
| 92250 |
|
275 |
236 |
$2K |
| 90740 |
|
17 |
13 |
$2K |
| 83935 |
|
1,590 |
1,352 |
$2K |
| 86777 |
|
1,039 |
831 |
$2K |
| 81267 |
|
304 |
251 |
$2K |
| 20600 |
|
14 |
12 |
$2K |
| 83789 |
|
373 |
321 |
$1K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
3,805 |
3,384 |
$1K |
| J3490 |
Unclassified drugs |
1,382,905 |
366,777 |
$1K |
| 82104 |
|
1,033 |
920 |
$1K |
| 82962 |
|
32,046 |
26,710 |
$1K |
| 29125 |
|
1,726 |
1,584 |
$1K |
| 92556 |
|
4,579 |
4,158 |
$1K |
| 11104 |
|
16 |
12 |
$1K |
| 70549 |
|
24 |
24 |
$1K |
| 82017 |
|
318 |
294 |
$1K |
| 81240 |
|
1,301 |
1,147 |
$1K |
| 84132 |
|
523,175 |
383,875 |
$1K |
| 11057 |
|
12 |
12 |
$1K |
| 82523 |
|
288 |
265 |
$1K |
| 82610 |
|
575 |
508 |
$1K |
| 82010 |
|
4,081 |
3,466 |
$1K |
| 82977 |
|
15,128 |
11,425 |
$1K |
| 84520 |
|
540,987 |
397,131 |
$1K |
| 83930 |
|
1,288 |
1,099 |
$1K |
| 86901 |
|
79,350 |
55,038 |
$1K |
| 89060 |
|
985 |
875 |
$1K |
| 72052 |
|
26 |
24 |
$1K |
| 0052A |
|
45 |
31 |
$1K |
| 95249 |
|
18 |
14 |
$1K |
| 90636 |
|
48 |
41 |
$1K |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
4,058 |
3,256 |
$1K |
| 82945 |
|
1,750 |
1,416 |
$1K |
| 11055 |
|
46 |
41 |
$1K |
| 84157 |
|
2,024 |
1,648 |
$1K |
| 80158 |
|
546 |
300 |
$1K |
| 86340 |
|
257 |
236 |
$1K |
| 93283 |
|
1,346 |
1,226 |
$1K |
| 84295 |
|
533,153 |
390,592 |
$997.02 |
| 88185 |
|
9,880 |
7,935 |
$970.28 |
| 0064A |
|
53 |
27 |
$960.00 |
| 84133 |
|
1,616 |
1,411 |
$957.63 |
| 87220 |
|
466 |
419 |
$956.45 |
| 80051 |
|
2,358 |
2,128 |
$954.90 |
| 87563 |
|
87 |
82 |
$933.28 |
| 86162 |
|
296 |
269 |
$931.20 |
| 80203 |
|
197 |
159 |
$911.52 |
| 93284 |
|
994 |
919 |
$861.71 |
| 84030 |
|
208 |
155 |
$854.69 |
| 92060 |
|
2,288 |
2,210 |
$815.29 |
| J2560 |
Injection, phenobarbital sodium, up to 120 mg |
15 |
13 |
$806.00 |
| 82436 |
|
1,189 |
1,039 |
$798.59 |
| 90715 |
|
11,770 |
10,565 |
$795.54 |
| 86337 |
|
142 |
130 |
$793.00 |
| J1643 |
Injection, heparin sodium (pfizer), not therapeutically equivalent to j1644, per 1000 units |
103 |
49 |
$788.93 |
| 85049 |
|
872 |
619 |
$774.18 |
| 85651 |
|
3,217 |
2,687 |
$747.80 |
| 89230 |
|
14 |
14 |
$744.51 |
| 12013 |
|
545 |
486 |
$730.57 |
| 82270 |
|
308 |
286 |
$705.97 |
| 94250 |
|
768 |
633 |
$704.67 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
136,051 |
93,970 |
$678.30 |
| 80180 |
|
231 |
205 |
$672.36 |
| 69200 |
|
707 |
652 |
$671.44 |
| 93922 |
|
13 |
12 |
$658.60 |
| 0003A |
|
31 |
18 |
$640.00 |
| 80074 |
|
296 |
217 |
$639.65 |
| 87305 |
|
1,970 |
1,010 |
$629.75 |
| 81241 |
|
966 |
836 |
$625.18 |
| 92597 |
|
14 |
12 |
$611.10 |
| 0111A |
|
39 |
17 |
$600.00 |
| 0053A |
|
33 |
17 |
$600.00 |
| 89050 |
|
1,941 |
1,395 |
$593.83 |
| 72114 |
|
59 |
55 |
$592.30 |
| 80195 |
|
439 |
229 |
$589.95 |
| 64643 |
|
1,154 |
1,062 |
$553.49 |
| 84075 |
|
376,761 |
293,031 |
$550.25 |
| 76942 |
|
4,846 |
4,414 |
$546.08 |
| 76380 |
|
12 |
12 |
$537.68 |
| 87207 |
|
729 |
658 |
$528.68 |
| 76776 |
|
17 |
14 |
$527.14 |
| 0051A |
|
31 |
16 |
$520.00 |
| 88173 |
|
1,679 |
1,487 |
$511.20 |
| 72200 |
|
30 |
25 |
$510.54 |
| 82180 |
|
223 |
203 |
$509.76 |
| 85250 |
|
238 |
215 |
$509.04 |
| 88313 |
|
4,222 |
3,576 |
$507.14 |
| 82731 |
|
21 |
16 |
$492.16 |
| 46600 |
|
148 |
137 |
$489.64 |
| 95012 |
|
11,697 |
10,162 |
$484.04 |
| 76872 |
|
62 |
56 |
$482.33 |
| 83529 |
|
104 |
98 |
$482.04 |
| 85270 |
|
228 |
215 |
$478.80 |
| 96376 |
|
35,475 |
22,437 |
$453.51 |
| 86382 |
|
16 |
16 |
$452.20 |
| 94727 |
|
12,945 |
9,182 |
$449.27 |
| 76999 |
|
13 |
13 |
$443.70 |
| 93282 |
|
286 |
258 |
$418.92 |
| 85247 |
|
113 |
107 |
$416.29 |
| 87147 |
|
393 |
368 |
$414.59 |
| 83037 |
|
6,721 |
6,358 |
$401.32 |
| 80050 |
General health panel |
787 |
570 |
$396.21 |
| 82075 |
|
8,069 |
5,634 |
$388.96 |
| 83918 |
|
83 |
74 |
$361.56 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
4,518 |
4,229 |
$351.38 |
| 84238 |
|
116 |
90 |
$349.20 |
| 71111 |
|
15 |
13 |
$348.63 |
| 74328 |
|
557 |
503 |
$320.78 |
| 87641 |
|
1,531 |
1,332 |
$317.08 |
| 93226 |
|
5,746 |
5,341 |
$309.29 |
| 99152 |
|
12,021 |
10,654 |
$302.64 |
| 82595 |
|
106 |
96 |
$290.46 |
| 88182 |
|
707 |
609 |
$282.34 |
| 84182 |
|
46 |
27 |
$274.88 |
| J9181 |
Injection, etoposide, 10 mg |
2,668 |
643 |
$269.04 |
| J9263 |
Injection, oxaliplatin, 0.5 mg |
8,198 |
2,851 |
$266.00 |
| C1726 |
Catheter, balloon dilatation, non-vascular |
715 |
652 |
$263.84 |
| 76981 |
|
439 |
420 |
$245.22 |
| A9502 |
Technetium tc-99m tetrofosmin, diagnostic, per study dose |
7,264 |
6,419 |
$235.68 |
| 87328 |
|
45 |
41 |
$229.00 |
| 82955 |
|
99 |
80 |
$212.75 |
| 90656 |
|
218 |
208 |
$211.75 |
| 81340 |
|
12 |
12 |
$199.51 |
| 81342 |
|
27 |
24 |
$192.43 |
| 99153 |
Mod sedat endo service >5yrs |
11,029 |
9,831 |
$191.98 |
| 76937 |
|
3,555 |
3,187 |
$191.96 |
| 81401 |
|
184 |
170 |
$191.80 |
| 93246 |
|
16 |
12 |
$191.13 |
| 51701 |
|
20 |
14 |
$189.24 |
| 17000 |
|
25 |
24 |
$182.77 |
| 93320 |
|
13,120 |
11,099 |
$174.00 |
| 84252 |
|
25 |
24 |
$166.80 |
| 82653 |
|
29 |
26 |
$160.68 |
| 82530 |
|
19 |
13 |
$159.60 |
| 94799 |
|
425 |
352 |
$157.23 |
| 81219 |
|
15 |
13 |
$155.38 |
| 84311 |
|
594 |
354 |
$153.64 |
| 81208 |
|
118 |
93 |
$153.60 |
| A9555 |
Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries |
2,779 |
2,491 |
$150.00 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
5,353 |
4,601 |
$147.04 |
| 84155 |
|
357,405 |
279,067 |
$144.64 |
| 82365 |
|
193 |
170 |
$135.41 |
| 87350 |
|
40 |
38 |
$132.12 |
| 86747 |
|
216 |
104 |
$129.24 |
| 82375 |
|
267 |
228 |
$117.70 |
| J9045 |
Injection, carboplatin, 50 mg |
11,638 |
4,538 |
$115.96 |
| J1805 |
Injection, esmolol hydrochloride, 10 mg |
900 |
453 |
$113.80 |
| 80069 |
|
140 |
119 |
$113.17 |
| 86707 |
|
38 |
36 |
$110.50 |
| 99407 |
|
413 |
332 |
$109.63 |
| 76376 |
|
11,309 |
10,248 |
$100.00 |
| 84540 |
|
247 |
220 |
$99.88 |
| 86774 |
|
89 |
80 |
$98.91 |
| 81257 |
|
128 |
114 |
$98.32 |
| 73565 |
|
13 |
13 |
$98.24 |
| 92583 |
|
605 |
563 |
$97.82 |
| 80047 |
|
964 |
738 |
$96.16 |
| 87899 |
|
68 |
65 |
$91.60 |
| 97130 |
|
201 |
62 |
$91.53 |
| 86684 |
|
29 |
28 |
$90.78 |
| 87176 |
|
282 |
193 |
$84.30 |
| 86778 |
|
121 |
98 |
$82.56 |
| 95886 |
|
4,618 |
4,333 |
$75.39 |
| J2785 |
Injection, regadenoson, 0.1 mg |
7,331 |
6,647 |
$72.00 |
| 87593 |
|
46 |
25 |
$67.02 |
| 85670 |
|
67 |
65 |
$66.12 |
| J1790 |
Injection, droperidol, up to 5 mg |
8,508 |
7,014 |
$65.86 |
| 93325 |
|
22,809 |
19,472 |
$65.60 |
| 80220 |
|
15 |
14 |
$65.40 |
| 80165 |
|
61 |
53 |
$63.74 |
| 11720 |
|
27 |
25 |
$62.69 |
| 84591 |
|
15 |
12 |
$61.68 |
| 82438 |
|
14 |
14 |
$54.36 |
| 88341 |
|
4,664 |
3,961 |
$50.74 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
6,673 |
4,573 |
$50.73 |
| 89055 |
|
42 |
39 |
$48.84 |
| 86060 |
|
12 |
12 |
$48.79 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
109,218 |
90,319 |
$46.06 |
| 94760 |
|
28,875 |
25,185 |
$43.91 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
13 |
12 |
$42.49 |
| 86687 |
|
156 |
117 |
$40.10 |
| 87181 |
|
94 |
83 |
$38.28 |
| 86790 |
|
53 |
41 |
$36.93 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
41,398 |
29,822 |
$36.88 |
| 84466 |
|
35 |
32 |
$36.57 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
112,512 |
88,412 |
$36.49 |
| C1769 |
Guide wire |
7,215 |
6,341 |
$35.65 |
| 84597 |
|
16 |
12 |
$35.56 |
| 82042 |
|
35 |
26 |
$34.58 |
| 82657 |
|
13 |
12 |
$34.48 |
| 88302 |
|
522 |
477 |
$34.40 |
| 87430 |
|
303 |
299 |
$34.35 |
| A9575 |
Injection, gadoterate meglumine, 0.1 ml |
58,672 |
42,265 |
$32.02 |
| C2617 |
Stent, non-coronary, temporary, without delivery system |
1,903 |
1,685 |
$29.29 |
| 88240 |
|
205 |
171 |
$28.95 |
| 93356 |
|
3,678 |
3,211 |
$28.23 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
24,036 |
18,013 |
$26.65 |
| 87185 |
|
306 |
262 |
$26.10 |
| G0472 |
Hepatitis c antibody screening, for individual at high risk and other covered indication(s) |
1,201 |
1,125 |
$23.90 |
| S5553 |
Insulin, long acting; 5 units |
3,494 |
1,362 |
$23.02 |
| J1836 |
Injection, metronidazole, 10 mg |
788 |
530 |
$22.63 |
| 85305 |
|
15 |
13 |
$22.16 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
122,989 |
95,094 |
$21.85 |
| 85347 |
|
2,262 |
1,979 |
$20.35 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
22,535 |
18,934 |
$19.52 |
| J1920 |
Injection, labetalol hydrochloride, 5 mg |
1,016 |
794 |
$18.12 |
| J2598 |
Injection, vasopressin, 1 unit |
200 |
137 |
$16.41 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
10,446 |
7,760 |
$15.10 |
| J8597 |
Antiemetic drug, oral, not otherwise specified |
9,639 |
7,966 |
$13.39 |
| 93291 |
|
32 |
25 |
$13.27 |
| 80162 |
|
27 |
24 |
$12.68 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
1,771 |
1,443 |
$12.60 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
43,605 |
32,434 |
$12.20 |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
3,840 |
3,387 |
$12.07 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
1,692 |
1,382 |
$11.97 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
83,885 |
61,603 |
$11.81 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
98,263 |
76,206 |
$11.25 |
| 86635 |
|
17 |
12 |
$10.96 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
60,818 |
50,592 |
$10.73 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
17,413 |
10,877 |
$8.62 |
| G0008 |
Administration of influenza virus vaccine |
2,473 |
2,348 |
$8.00 |
| J1939 |
Injection, bumetanide, 0.5 mg |
50 |
26 |
$7.68 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
3,515 |
3,031 |
$6.91 |
| J2704 |
Injection, propofol, 10 mg |
5,908 |
4,470 |
$6.26 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
36,690 |
29,654 |
$6.00 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
17,239 |
12,581 |
$4.84 |
| J8499 |
Prescription drug, oral, non chemotherapeutic, nos |
172 |
146 |
$4.08 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
27,952 |
13,943 |
$3.97 |
| J1815 |
Injection, insulin, per 5 units |
20,902 |
7,238 |
$3.90 |
| G0475 |
Hiv antigen/antibody, combination assay, screening |
902 |
855 |
$3.87 |
| J9260 |
Injection, methotrexate sodium, 50 mg |
1,198 |
701 |
$2.50 |
| C9113 |
Injection, pantoprazole sodium, per vial |
3,846 |
1,802 |
$2.40 |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
36,525 |
14,836 |
$2.30 |
| G8980 |
Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting |
334 |
289 |
$2.28 |
| J0295 |
Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm |
4,079 |
1,687 |
$2.12 |
| G8985 |
Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
253 |
232 |
$2.08 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
40,507 |
34,146 |
$2.07 |
| S0028 |
Injection, famotidine, 20 mg |
119 |
68 |
$2.00 |
| G8984 |
Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals |
215 |
197 |
$1.74 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
492 |
354 |
$1.50 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
21,710 |
9,574 |
$1.39 |
| J1644 |
Injection, heparin sodium, per 1000 units |
31,714 |
12,423 |
$1.35 |
| 96368 |
|
6,918 |
4,073 |
$1.28 |
| J1953 |
Injection, levetiracetam, 10 mg |
1,076 |
783 |
$1.25 |
| J9370 |
Vincristine sulfate, 1 mg |
3,112 |
1,976 |
$1.25 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
131 |
95 |
$1.00 |
| J3480 |
Injection, potassium chloride, per 2 meq |
4,874 |
2,749 |
$0.93 |
| G8988 |
Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
132 |
112 |
$0.77 |
| G8987 |
Self care functional limitation, current status, at therapy episode outset and at reporting intervals |
96 |
82 |
$0.57 |
| J1630 |
Injection, haloperidol, up to 5 mg |
5,459 |
4,334 |
$0.48 |
| J7042 |
5% dextrose/normal saline (500 ml = 1 unit) |
3,072 |
2,288 |
$0.44 |
| J3030 |
Injection, sumatriptan succinate, 6 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) |
176 |
140 |
$0.22 |
| G8997 |
Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
98 |
82 |
$0.20 |
| G8996 |
Swallowing functional limitation, current status at therapy episode outset and at reporting intervals |
98 |
82 |
$0.20 |
| G8998 |
Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting |
96 |
81 |
$0.18 |
| G8982 |
Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
15 |
14 |
$0.10 |
| G8981 |
Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals |
15 |
14 |
$0.10 |
| Q0163 |
Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen |
686 |
523 |
$0.06 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
20,159 |
13,946 |
$0.03 |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
7,794 |
6,849 |
$0.00 |
| 95885 |
|
3,192 |
3,035 |
$0.00 |
| J2543 |
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) |
4,507 |
1,618 |
$0.00 |
| 64494 |
|
1,288 |
1,170 |
$0.00 |
| 51797 |
|
1,335 |
1,225 |
$0.00 |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
31,016 |
15,943 |
$0.00 |
| A9567 |
Technetium tc-99m pentetate, diagnostic, aerosol, per study dose, up to 75 millicuries |
97 |
76 |
$0.00 |
| J3471 |
Injection, hyaluronidase, ovine, preservative free, per 1 usp unit (up to 999 usp units) |
13 |
12 |
$0.00 |
| J3535 |
Drug administered through a metered dose inhaler |
10,843 |
8,780 |
$0.00 |
| 36416 |
|
17,754 |
9,062 |
$0.00 |
| A9503 |
Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries |
2,089 |
1,906 |
$0.00 |
| C1889 |
Implantable/insertable device, not otherwise classified |
3,716 |
3,282 |
$0.00 |
| C1781 |
Mesh (implantable) |
1,459 |
1,330 |
$0.00 |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
11,103 |
8,525 |
$0.00 |
| J2700 |
Injection, oxacillin sodium, up to 250 mg |
34 |
14 |
$0.00 |
| J0360 |
Injection, hydralazine hcl, up to 20 mg |
2,458 |
1,973 |
$0.00 |
| J2920 |
Injection, methylprednisolone sodium succinate, up to 40 mg |
4,197 |
2,938 |
$0.00 |
| J1720 |
Injection, hydrocortisone sodium succinate, up to 100 mg |
3,584 |
2,527 |
$0.00 |
| 99070 |
|
796 |
560 |
$0.00 |
| J0461 |
Injection, atropine sulfate, 0.01 mg |
3,927 |
1,901 |
$0.00 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
3,001 |
2,633 |
$0.00 |
| L8699 |
Prosthetic implant, not otherwise specified |
1,551 |
1,425 |
$0.00 |
| 77001 |
|
2,173 |
1,978 |
$0.00 |
| 64484 |
|
224 |
210 |
$0.00 |
| A9698 |
Non-radioactive contrast imaging material, not otherwise classified, per study |
1,280 |
1,209 |
$0.00 |
| G0009 |
Administration of pneumococcal vaccine |
389 |
375 |
$0.00 |
| 99156 |
|
147 |
134 |
$0.00 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
9,461 |
7,341 |
$0.00 |
| 0482T |
|
711 |
628 |
$0.00 |
| J1940 |
Injection, furosemide, up to 20 mg |
5,028 |
3,378 |
$0.00 |
| J2060 |
Injection, lorazepam, 2 mg |
12,711 |
9,306 |
$0.00 |
| C1730 |
Catheter, electrophysiology, diagnostic, other than 3d mapping (19 or fewer electrodes) |
135 |
119 |
$0.00 |
| J7999 |
Compounded drug, not otherwise classified |
11,255 |
9,243 |
$0.00 |
| 0399T |
|
214 |
191 |
$0.00 |
| Q9965 |
Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml |
6,858 |
5,669 |
$0.00 |
| Q0175 |
Perphenazine, 4 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
409 |
87 |
$0.00 |
| C9290 |
Injection, bupivacaine liposome, 1 mg |
231 |
177 |
$0.00 |
| J3411 |
Injection, thiamine hcl, 100 mg |
3,853 |
2,064 |
$0.00 |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
11,743 |
7,901 |
$0.00 |
| J9267 |
Injection, paclitaxel, 1 mg |
12,941 |
3,809 |
$0.00 |
| V2632 |
Posterior chamber intraocular lens |
2,876 |
2,365 |
$0.00 |
| 93788 |
|
273 |
247 |
$0.00 |
| A9540 |
Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries |
163 |
135 |
$0.00 |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
195 |
177 |
$0.00 |
| 88311 |
|
3,103 |
2,648 |
$0.00 |
| 87071 |
|
424 |
357 |
$0.00 |
| J2371 |
Injection, phenylephrine hydrochloride, 20 micrograms |
1,516 |
1,237 |
$0.00 |
| 91305 |
|
600 |
408 |
$0.00 |
| C1830 |
Powered bone marrow biopsy needle |
82 |
75 |
$0.00 |
| J3360 |
Injection, diazepam, up to 5 mg |
1,468 |
1,177 |
$0.00 |
| 76377 |
|
2,837 |
2,561 |
$0.00 |
| C1725 |
Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) |
916 |
800 |
$0.00 |
| J0697 |
Injection, sterile cefuroxime sodium, per 750 mg |
979 |
790 |
$0.00 |
| J0610 |
Injection, calcium gluconate (fresenius kabi), per 10 ml |
2,630 |
1,698 |
$0.00 |
| J0280 |
Injection, aminophyllin, up to 250 mg |
982 |
887 |
$0.00 |
| C1819 |
Surgical tissue localization and excision device (implantable) |
500 |
451 |
$0.00 |
| C1759 |
Catheter, intracardiac echocardiography |
17 |
14 |
$0.00 |
| J7050 |
Infusion, normal saline solution, 250 cc |
33,250 |
20,331 |
$0.00 |
| 64488 |
|
58 |
52 |
$0.00 |
| J2470 |
Injection, pantoprazole sodium, 40 mg |
231 |
114 |
$0.00 |
| J9250 |
Methotrexate sodium, 5 mg |
648 |
285 |
$0.00 |
| 88331 |
|
646 |
556 |
$0.00 |
| A4648 |
Tissue marker, implantable, any type, each |
1,593 |
1,399 |
$0.00 |
| S0020 |
Injection, bupivicaine hydrochloride, 30 ml |
489 |
315 |
$0.00 |
| 84260 |
|
14 |
13 |
$0.00 |
| 81000 |
|
123 |
117 |
$0.00 |
| 81511 |
|
121 |
109 |
$0.00 |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
437 |
234 |
$0.00 |
| C1893 |
Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away |
29 |
26 |
$0.00 |
| C1732 |
Catheter, electrophysiology, diagnostic/ablation, 3d or vector mapping |
31 |
27 |
$0.00 |
| 99406 |
|
15 |
13 |
$0.00 |
| 91307 |
|
447 |
435 |
$0.00 |
| C1778 |
Lead, neurostimulator (implantable) |
31 |
27 |
$0.00 |
| 91303 |
|
1,835 |
868 |
$0.00 |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
752 |
683 |
$0.00 |
| J0173 |
Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg |
43 |
37 |
$0.00 |
| 51600 |
|
323 |
301 |
$0.00 |
| 82810 |
|
16 |
13 |
$0.00 |
| 88348 |
|
25 |
24 |
$0.00 |
| C1753 |
Catheter, intravascular ultrasound |
83 |
70 |
$0.00 |
| 93290 |
|
13 |
12 |
$0.00 |
| 77417 |
|
51 |
27 |
$0.00 |
| C1886 |
Catheter, extravascular tissue ablation, any modality (insertable) |
87 |
84 |
$0.00 |
| 11045 |
|
19 |
13 |
$0.00 |
| 91301 |
|
7,843 |
7,235 |
$0.00 |
| 88150 |
|
13 |
12 |
$0.00 |
| 49424 |
|
74 |
54 |
$0.00 |
| J2790 |
Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) |
168 |
142 |
$0.00 |
| Q9963 |
High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml |
16 |
14 |
$0.00 |
| 43273 |
|
26 |
24 |
$0.00 |
| Q0164 |
Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
41 |
39 |
$0.00 |
| 61782 |
|
45 |
40 |
$0.00 |
| 36247 |
|
17 |
15 |
$0.00 |
| 30901 |
|
85 |
82 |
$0.00 |
| J2791 |
Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu |
84 |
74 |
$0.00 |
| A9585 |
Injection, gadobutrol, 0.1 ml |
17 |
16 |
$0.00 |
| 81255 |
|
31 |
27 |
$0.00 |
| J0713 |
Injection, ceftazidime, per 500 mg |
37 |
14 |
$0.00 |
| C1766 |
Introducer/sheath, guiding, intracardiac electrophysiological, steerable, other than peel-away |
45 |
37 |
$0.00 |
| 82360 |
|
30 |
26 |
$0.00 |
| J7507 |
Tacrolimus, immediate release, oral, 1 mg |
32 |
12 |
$0.00 |
| 11730 |
|
13 |
13 |
$0.00 |
| J2404 |
Injection, nicardipine, 0.1 mg |
24 |
13 |
$0.00 |
| C2625 |
Stent, non-coronary, temporary, with delivery system |
516 |
461 |
$0.00 |
| 78434 |
|
1,890 |
1,715 |
$0.00 |
| J9201 |
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg |
6,130 |
1,993 |
$0.00 |
| Q9957 |
Injection, perflutren lipid microspheres, per ml |
9,105 |
8,115 |
$0.00 |
| A9552 |
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries |
6,515 |
5,907 |
$0.00 |
| 93321 |
|
4,223 |
3,770 |
$0.00 |
| J1050 |
Injection, medroxyprogesterone acetate, 1 mg |
3,453 |
3,301 |
$0.00 |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
6,858 |
5,921 |
$0.00 |
| J1756 |
Injection, iron sucrose, 1 mg |
10,613 |
4,079 |
$0.00 |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
4,792 |
4,218 |
$0.00 |
| 00170 |
Anesthesia for intraoral procedures, including biopsy |
30 |
27 |
$0.00 |
| 92978 |
|
53 |
41 |
$0.00 |
| Q9958 |
High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml |
1,078 |
704 |
$0.00 |
| J9206 |
Injection, irinotecan, 20 mg |
5,638 |
2,063 |
$0.00 |
| J9999 |
Not otherwise classified, antineoplastic drugs |
2,746 |
1,099 |
$0.00 |
| 58340 |
|
272 |
255 |
$0.00 |
| J1580 |
Injection, garamycin, gentamicin, up to 80 mg |
1,927 |
1,538 |
$0.00 |
| 77002 |
|
3,992 |
3,620 |
$0.00 |
| 95874 |
|
676 |
602 |
$0.00 |
| J9060 |
Injection, cisplatin, powder or solution, 10 mg |
3,755 |
1,244 |
$0.00 |
| 94729 |
|
15,457 |
10,922 |
$0.00 |
| J1071 |
Injection, testosterone cypionate, 1 mg |
778 |
374 |
$0.00 |
| 99177 |
|
573 |
546 |
$0.00 |
| J2710 |
Injection, neostigmine methylsulfate, up to 0.5 mg |
1,571 |
1,413 |
$0.00 |
| C1760 |
Closure device, vascular (implantable/insertable) |
2,083 |
1,843 |
$0.00 |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
5,895 |
5,359 |
$0.00 |
| J9190 |
Injection, fluorouracil, 500 mg |
17,356 |
4,786 |
$0.00 |
| 88312 |
|
1,954 |
1,756 |
$0.00 |
| Q0144 |
Azithromycin dihydrate, oral, capsules/powder, 1 gram |
521 |
473 |
$0.00 |
| C1874 |
Stent, coated/covered, with delivery system |
879 |
758 |
$0.00 |
| J1240 |
Injection, dimenhydrinate, up to 50 mg |
2,927 |
2,486 |
$0.00 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
13,062 |
8,080 |
$0.00 |
| 75565 |
|
2,185 |
1,991 |
$0.00 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
33,848 |
19,704 |
$0.00 |
| 76827 |
|
5,047 |
4,330 |
$0.00 |
| J0640 |
Injection, leucovorin calcium, per 50 mg |
9,532 |
3,953 |
$0.00 |
| C1788 |
Port, indwelling (implantable) |
1,390 |
1,267 |
$0.00 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
9,119 |
8,241 |
$0.00 |
| J3489 |
Injection, zoledronic acid, 1 mg |
3,336 |
2,874 |
$0.00 |
| 77387 |
|
4,703 |
545 |
$0.00 |
| Q9954 |
Oral magnetic resonance contrast agent, per 100 ml |
8,079 |
6,471 |
$0.00 |
| C1782 |
Morcellator |
102 |
96 |
$0.00 |
| J0744 |
Injection, ciprofloxacin for intravenous infusion, 200 mg |
1,361 |
1,105 |
$0.00 |
| J1596 |
Injection, glycopyrrolate, 0.1 mg |
1,861 |
1,578 |
$0.00 |
| J2274 |
Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg |
214 |
201 |
$0.00 |
| J3370 |
Injection, vancomycin hcl, 500 mg |
6,763 |
4,115 |
$0.00 |
| C1776 |
Joint device (implantable) |
1,177 |
1,070 |
$0.00 |
| 99151 |
|
1,107 |
1,009 |
$0.00 |
| J9000 |
Injection, doxorubicin hydrochloride, 10 mg |
3,903 |
1,623 |
$0.00 |
| J3473 |
Injection, hyaluronidase, recombinant, 1 usp unit |
655 |
613 |
$0.00 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
2,000 |
1,756 |
$0.00 |
| J2004 |
Injection, lidocaine hcl with epinephrine, 1 mg |
548 |
460 |
$0.00 |
| 81243 |
|
43 |
38 |
$0.00 |
| C1887 |
Catheter, guiding (may include infusion/perfusion capability) |
1,814 |
1,611 |
$0.00 |
| 77012 |
|
2,017 |
1,725 |
$0.00 |
| 86904 |
|
175 |
152 |
$0.00 |
| 88344 |
|
65 |
56 |
$0.00 |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
129 |
93 |
$0.00 |
| A9541 |
Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries |
1,046 |
938 |
$0.00 |
| A4222 |
Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately) |
6,003 |
3,351 |
$0.00 |
| 99173 |
|
1,038 |
991 |
$0.00 |
| 92504 |
|
465 |
426 |
$0.00 |
| C1729 |
Catheter, drainage |
1,389 |
1,157 |
$0.00 |
| 90461 |
|
5,657 |
5,390 |
$0.00 |
| Q9956 |
Injection, octafluoropropane microspheres, per ml |
350 |
335 |
$0.00 |
| J3371 |
Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg |
393 |
229 |
$0.00 |
| C1758 |
Catheter, ureteral |
1,289 |
1,071 |
$0.00 |
| A9520 |
Technetium tc-99m tilmanocept, diagnostic, up to 0.5 millicuries |
45 |
37 |
$0.00 |
| J7510 |
Prednisolone oral, per 5 mg |
221 |
188 |
$0.00 |
| 91300 |
|
30,594 |
25,466 |
$0.00 |
| J3260 |
Injection, tobramycin sulfate, up to 80 mg |
938 |
764 |
$0.00 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
39,961 |
29,509 |
$0.00 |
| 81420 |
Fetal chromosomal aneuploidy genomic sequence analysis panel |
388 |
367 |
$0.00 |
| 81403 |
|
73 |
61 |
$0.00 |
| 75571 |
|
12 |
12 |
$0.00 |
| 16020 |
|
43 |
39 |
$0.00 |
| C1751 |
Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) |
15 |
12 |
$0.00 |
| 92015 |
Determination of refractive state |
390 |
377 |
$0.00 |
| 77003 |
|
15 |
14 |
$0.00 |
| 81406 |
|
80 |
71 |
$0.00 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
1,664 |
1,306 |
$0.00 |
| J2720 |
Injection, protamine sulfate, per 10 mg |
432 |
349 |
$0.00 |
| 76001 |
|
136 |
115 |
$0.00 |
| 62322 |
|
46 |
44 |
$0.00 |
| 81404 |
|
79 |
69 |
$0.00 |
| 91312 |
|
219 |
199 |
$0.00 |
| 88381 |
|
139 |
104 |
$0.00 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
567 |
416 |
$0.00 |
| 99442 |
|
213 |
161 |
$0.00 |
| 80143 |
|
139 |
117 |
$0.00 |
| 95887 |
|
38 |
38 |
$0.00 |
| 64495 |
|
50 |
43 |
$0.00 |
| 64636 |
|
13 |
12 |
$0.00 |
| 90648 |
|
28 |
24 |
$0.00 |
| G0500 |
Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) |
16 |
16 |
$0.00 |
| 92134 |
|
14 |
14 |
$0.00 |
| J0137 |
Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg |
43 |
29 |
$0.00 |
| 90653 |
|
172 |
168 |
$0.00 |
| 95018 |
|
33 |
27 |
$0.00 |
| J7517 |
Mycophenolate mofetil, oral, 250 mg |
105 |
42 |
$0.00 |
| C1762 |
Connective tissue, human (includes fascia lata) |
16 |
12 |
$0.00 |
| 91311 |
|
44 |
34 |
$0.00 |
| J0882 |
Injection, darbepoetin alfa, 1 microgram (for esrd on dialysis) |
17 |
12 |
$0.00 |
| 99157 |
|
53 |
51 |
$0.00 |
| 75774 |
|
12 |
12 |
$0.00 |
| 81422 |
|
40 |
38 |
$0.00 |
| 69209 |
|
14 |
12 |
$0.00 |
| 93613 |
|
17 |
14 |
$0.00 |
| C1876 |
Stent, non-coated/non-covered, with delivery system |
16 |
13 |
$0.00 |